

Sungrace Pharma Private Limited

5th Annual Report 2022-23

INDEPENDENT AUDITORS' REPORT

To the Members of
Sungrace Pharma Private Limited

Report on the Audit of the Standalone Financial Statements

Opinion

01. We have audited the accompanying financial statements of Sungrace Pharma Private Limited (the "Company"), which comprise the Balance Sheet as at 31st March, 2023, the Statement of Profit and Loss (including Other Comprehensive Income), the Statement of Changes in Equity and Cash Flow Statement for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.
02. In our opinion, and to the best of our information and according to the explanations given to us, the the aforesaid standalone financial statements give the information required by the Companies Act, 2013 in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the company as at 31st March, 2023; its profit including other comprehensive income, its cash flows and the changes in equity for the year ended on that date.

Basis for Opinion

03. We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Information other than the Financial Statements and Auditor's Report thereon

04. The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Board's Report including Annexures to Board's Report, management report but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.



Responsibilities of Management and Those Charged with Governance for the Standalone Financial Statements

05. The Company's management and Board of Directors are responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the state of affairs, profit/loss and other comprehensive income, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.
06. In preparing the financial statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
07. Those Board of Directors are also responsible for overseeing the company's financial reporting process.


Auditor's Responsibilities for the Audit of the Financial Statements

08. Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
09. As part of an audit in accordance with Standards on Auditing, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for explaining our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
 - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
 - Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
 - Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
10. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
11. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

12. As required by the Companies (Auditor's Report) Order, 2016 ("the Order") issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, and on the basis of such checks of the books and records of the company as we considered appropriate and according to the information and explanations given to us, we give in the 'Annexure A', a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
13. As required by section 143(3) of the Act, we report that:
- a) we have sought and obtained all the information and explanations, which to the best of our knowledge and belief were necessary for the purpose of our audit;



- b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
- c) The Balance Sheet, the Statement of Profit and Loss including the Statement of Other Comprehensive Income, the Cash Flow Statement and Statement of Changes in Equity dealt with by this Report are in agreement with the books of account;
- d) In our opinion, the aforesaid standalone financial statements comply with the Indian Accounting Standards specified under Section 133 of the Act;
- e) On the basis of written representations received from the Directors as on 31st March, 2023 and taken on record by the Board of Directors, we report that none of the Directors is disqualified as on 31st March, 2023 from being appointed as a Director in terms of Section 164 (2) of the Act.
- f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in 'Annexure B'. Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls over financial reporting.
- g) With respect to the matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended:

In our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the current year is in accordance with the provisions of section 197 of the Act.

- h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - (i) The Company does not have any pending litigations which would impact its financial position.
 - (ii) The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - (iii) There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
 - (iv)
 - (a) The management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person or entity, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

- (b) The management has represented that, to the best of its knowledge no funds have been received by the company from any person or entity, ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
- (c) Based on such audit procedures that were considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (a) and (b) contain any material misstatement.
- (v) Since the Company has not declared or paid any dividend during the year, the question of commenting on whether dividend declared or paid is in accordance with Section 123 of the Companies Act, 2013 does not arise.

For, B H MANGAROLIA & CO.

Chartered Accountants

(FRN 105972W)

P. B. Mangarolia

(P B MANGAROLIA)

Partner

M. No. 124424

UDIN:23124424BGXRCW5995



Place: Ahmedabad

Date: 29.05.2023

ANNEXURE 'A' TO INDEPENDENT AUDITORS' REPORT

[Referred to in Paragraph 12 of our Report of even date]

01. a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment.
(B) The Company has not acquired any Intangible Assets and hence reporting under clause 3(i)(a)(B) of the Order is not applicable.
- b) Property, Plant and Equipment have been physically verified by the management during the year and no material discrepancies were identified on such verification.
- c) The Company has not acquired any Immovable properties and hence reporting under clause 3(i)(c) of the Order is not applicable.
- d) The Company has not revalued its Property, Plant and Equipment (including Right of use assets) or Intangible Assets during the year ended March 31, 2023.
- e) There are no proceedings initiated or are pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder.
02. (a) The inventory has been physically verified by the management during the year. In our opinion, the frequency of verification by the management is reasonable and the coverage and procedure for such verification is appropriate. No material discrepancies in aggregate for each class of inventory were noted on physical verification of inventory.
- (b) According to information and explanations given to us and relevant records produced, the company has not been sanctioned working capital limits in excess of Five Crore rupees and hence reporting under clause 3(ii)(b) of the Order is not applicable.
03. (a) During the year the Company has not provided loans, advances in the nature of loans, stood guarantee or provided security to Companies, Firms, Limited Liability Partnerships or any other parties. Accordingly, the requirement to report on clause 3(iii)(a) of the Order is not applicable to the Company.
- (b) During the year the Company has not made investments, provided guarantees, provided security and granted loans and advances in the nature of loans to Companies, Firms, Limited Liability Partnerships or any other parties. Accordingly, the requirement to report on clause 3(iii)(b) of the Order is not applicable to the Company.
- (c) The Company has not granted loans and advances in the nature of loans to companies, firms, Limited Liability Partnerships or any other parties. Accordingly, the requirement to report on clause 3(iii)(c), (d), (e) and (f) of the Order are not applicable to the Company.



04. In our opinion and according to the information and explanations given to us, provisions of section 186 of the Act in respect of investments made have been complied with by the Company. Further, in our opinion and according to the information and explanations given to us, there are no loans, guarantees, and securities given in respect of which provisions of section 185 and 186 of the Act are applicable. Accordingly, the requirement to report on clause 3(iv) of the Order is not applicable to that extent to the Company.
05. The Company has neither accepted any deposits from the public nor accepted any amounts which are deemed to be deposits within the meaning of sections 73 to 76 of the Companies Act and the rules made thereunder, to the extent applicable. Accordingly, the requirement to report on clause 3(v) of the Order is not applicable to the Company.
06. As informed and explained to us, the maintenance of Cost records U/s. 148(1) of the Act is not applicable to the company.
07. a) According to information and explanations given to us, the company is generally regular in depositing with Appropriate Authorities undisputed statutory dues including Income Tax, Goods and Services Tax and other material statutory dues applicable to it. According to the information and explanations given to us, there were no undisputed amounts payable in respect of such dues which were outstanding as on 31st March, 2023 for a period of more than six months from the date they became payable.
- b) According to the information and explanations given to us there are no any disputed dues which have not been deposited, of Income Tax, Goods and Services Tax as at 31st March, 2023 and therefore no further information is required to be furnished under this clause.
08. The Company has not surrendered or disclosed any transaction, previously unrecorded in the books of account, in the tax assessments under the Income Tax Act, 1961 as income during the year. Accordingly, the requirement to report on clause 3(viii) of the Order is not applicable to the Company.
09. a) The Company has not defaulted in repayment of loans or other borrowings or in the payment of interest thereon to any lender.
- b) The Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.
- c) The Company did not have any term loans outstanding during the year hence, the requirement to report on clause 3(ix)(c) of the Order is not applicable to the Company.
- d) On an overall examination of the financial Statements of the Company, no funds raised on short-term basis have been used for long-term purposes by the Company.



- e) On an overall examination of the financial Statements of the Company, the Company has not taken any funds from any entity or person on account of or to meet the obligations of its Subsidiary.
- f) The Company has not raised loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies. Hence, the requirement to report on clause 3(ix)(f) of the Order is not applicable to the Company.
10. a) The Company has not raised any money during the year by way of initial public offer / further public offer (including debt instruments) hence, the requirement to report on clause 3(x)(a) of the Order is not applicable to the Company.
- b) The Company has not made any preferential allotment or private placement of shares /fully or partially or optionally convertible debentures during the year under audit and hence, the requirement to report on clause 3(x)(b) of the Order is not applicable to the Company.
11. a) During the course of our examination of the books and records of the company, carried out in accordance with the generally accepted auditing practices in India and according to the information and explanations given to us, we have neither come across any instance of fraud on or by the company, noticed or reported during the year, nor we have been informed of such case by the management.
- b) During the year, no report under sub-section (12) of section 143 of the Companies Act, 2013 has been filed auditors in Form ADT - 4 as prescribed under Rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government.
- c) As represented to us by the management, there are no whistle blower complaints received by the Company during the year.
12. a) The Company is not a nidhi Company as per the provisions of the Companies Act, 2013. Therefore, the requirement to report on clause 3(xii)(a) (b) and (c) of the Order is not applicable to the Company.
13. According to the information and explanations given to us and based on our examinations of the records of the Company, transactions with the related parties are in compliance with section 188 of the Act, where applicable. The details of such related party transactions have been disclosed in the standalone financial statements as required by applicable Indian Accounting Standards. The provisions of section 177 are not applicable to the company and accordingly reporting under clause 3(xiii) insofar it relates to section 177 of the Act is not applicable to the company.
14. a) In our opinion and based on our examination, the company does not have an Internal audit system and is not required to have an internal audit system as per the provision of the Companies Act, 2013.



15. In our opinion and according to the information and explanations given to us, during the year the Company has not entered into any non-cash transactions with its Directors or persons connected to its Directors and hence reporting under clause 3(xv) of the Order is not applicable to the Company.
16. a) The company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, the reporting under Clause 3(xvi)(a) of the Order is not applicable to the Company.
- b) The Company has not conducted non-banking financial / housing finance activities during the year. Accordingly, the reporting under Clause 3(xvi)(b) of the Order is not applicable to the Company.
- c) The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, the reporting under Clause 3(xvi)(c) of the Order is not applicable to the Company.
- d) There is no Core Investment Company as a part of the Group, hence, the requirement to report on clause 3(xvi) of the Order is not applicable to the Company.
17. The Company has not incurred cash losses in the current year and in the immediately preceding financial year.
18. There has been no resignation of the statutory auditors during the year and accordingly requirement to report on Clause 3(xviii) of the Order is not applicable to the Company.
19. On the basis of the financial ratios disclosed in note 33 to the financial Statements, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial Statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.
20. According to the information and explanations given to us, the company does not fulfil the criteria as specified under section 135(1) of the Act read with the Companies (Corporate Social Responsibility Policy) Rules, 2014 and accordingly reporting under clause 3(xx) of the Order is not applicable to the Company.



21. The reporting under Clause 3(xxi) of the Order is not applicable in respect of audit of standalone financial statements. Accordingly, no comment in respect of the said clause has been included in this report.

For, B H MANGAROLIA & CO.

Chartered Accountants
(FRN 105972W)



(P B MANGAROLIA)

Partner

M. No. 124424

UDIN:23124424BGXRCW5995

Place: Ahmedabad
Date: 29.05.2023



ANNEXURE 'B' TO INDEPENDENT AUDITORS' REPORT

[Referred to in Paragraph 13(f) of our Report of even date]

Report on the Internal Financial Controls Over Financial Reporting under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ('the Act')

We have audited the internal financial controls over financial reporting of Sungrace Pharma Private Limited (the "Company"), as of 31st March, 2023, in conjunction with our audit of the standalone financial statements of the Company for the year ended as on that date.

Management's Responsibility for Internal Financial Controls


The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (the 'Guidance Note'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Standards on Auditing prescribed under Section 143(10) of the Act and the Guidance Note, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with the ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the standalone financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.



Meaning of Internal Financial Controls Over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial controls over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, to the best of our information and according to the explanations given to us, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31st March, 2023, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note.

For, B H MANGAROLIA & CO.

Chartered Accountants

(FRN 105972W)



(P B MANGAROLIA)

Partner

M. No. 124424

UDIN:23124424BGXRCW5995



Place: Ahmedabad

Date: 29.05.2023

Sungrace Pharma Private Limited
Balance Sheet as at 31st March, 2023

(₹ '000)

PARTICULARS	Note No.	As at 31.03.2023	As at 31.03.2022
I ASSETS			
Non-current assets			
Property, Plant and Equipment	03	113.38	289.96
Financial Assets			
i. Investments	04	100.01	50.01
ii. Trade receivables		-	-
Deferred Tax Assets (Net)	05	107.50	0.07
Other Non-current Assets	06	2,250.00	1,750.00
Total Non-current assets		2,570.89	2,090.03
Current assets			
Inventories	07	12,332.28	15,472.84
Financial Assets			
i. Investments		-	-
ii. Trade receivables	08	20,676.45	19,590.53
iii. Cash and Cash Equivalents	09	1,502.88	1,407.21
Current Tax Assets (Net)		-	-
Other Current Assets	10	126.42	813.91
Total Current assets		34,638.04	37,284.49
TOTAL ASSETS		37,208.93	39,374.52
II EQUITY AND LIABILITIES			
Equity			
Equity share capital	11	260.00	260.00
Other equity	12	13,340.29	10,287.12
Total Equity		13,600.29	10,547.12
Liabilities			
Non-current Liabilities			
Financial Liabilities			
i. Borrowings	13	230.40	1,304.55
ii. Trade Payable		-	-
Provisions	14	354.26	-
Other non current liabilities		-	-
Total Non-current liabilities		584.66	1,304.55
Current Liabilities			
Financial Liabilities			
i. Borrowings	15	12,511.07	12,042.52
ii. Trade Payable due to	16		
Micro and Small Enterprises		2,859.93	6,724.29
Other than Micro and Small Enterprises		5,848.58	4,131.42
iii. Other financial liabilities		-	-
Provisions	17	0.96	-
Other current liabilities	18	1,536.98	4,155.77
Current tax liabilities (net)	19	266.45	468.87
Total Current Liabilities		23,023.98	27,522.86
Total Liabilities		23,608.64	28,827.41
TOTAL EQUITY AND LIABILITIES		37,208.93	39,374.52

Significant Accounting Policies 02

See accompanying notes forming part of the financial statements

As per our report of even date

For, B H MANGAROLIA & CO.

Chartered Accountants

(FRN 105972W)

(Signature)

(P B MANGAROLIA) UDIN:23124424BGXRCW5995 (Sharad B. Shah)

Partner

M. No. 124424



For and on behalf of the Board

(Signature)

(Ronak K. Shah)

Director

DIN:03350856

Place: Ahmedabad Director

Date: 29.05.2023 DIN:00747131

Sungrace Pharma Private Limited

Statement of Profit and Loss for the year ended 31st March, 2023

(₹ '000)

PARTICULARS	Note No.	For the year ended	
		31.03.2023	31.03.2022
I. Revenue from operations	20	53,046.55	86,188.32
II. Other income	21	1,466.37	184.00
III. Total Income (I + II)		54,512.92	86,372.32
IV. Expenses			
a. Cost of materials consumed		-	-
b. Purchases of stock-in-trade	22	36,511.85	64,536.27
c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	23	3,140.56	2,574.95
d. Employee benefits expense	24	5,429.21	4,522.24
e. Finance costs	25	1,204.68	1,634.99
f. Depreciation and amortisation expense	26	176.58	70.83
g. Other expenses	27	3,944.31	8,705.69
Total expenses		50,407.19	82,044.97
V. Profit / (Loss) before exceptional items and tax (III - IV)		4,105.74	4,327.35
VI. Exceptional items		-	-
VII. Profit / (Loss) before tax (V - VI)		4,105.74	4,327.35
VIII Tax expense:			
a. Current Tax		1,160.00	1,115.00
b. Deferred Tax		(107.44)	0.24
		1,052.56	1,115.24
IX. Profit / (Loss) for the period from continuing operations (VII - VIII)		3,053.17	3,212.11
X. Profit / (Loss) from discontinuing operations		-	-
XI. Tax expense of discontinuing operations		-	-
XII. Profit/(loss) from Discontinuing operations (after tax) (X-XI)		-	-
XIII. Profit (Loss) for the period (IX + XII)		3,053.17	3,212.11
XIV. Other comprehensive income		-	-
Items that will not be reclassified to profit or loss		-	-
Income tax relating to item that will not be reclassified to profit or loss		-	-
XV. Total comprehensive income for the period (XIII + XIV)		-	-
XVI. Earnings per equity share	28		
a. Basic / Diluted Earnings per share (in ₹)		117.43	123.54
Significant Accounting Policies	02		

See accompanying notes forming part of the financial statements

As per our report of even date

For, B H MANGAROLIA & CO.

Chartered Accountants

(FRN 105972W)

[Signature]

(P B MANGAROLIA)

Partner

M. No. 124424



UDIN:23124424BGXRCW5995

Place: Ahmedabad

Date: 29.05.2023

For and on behalf of the Board

[Signature]

(Sharad B. Shah)

Director

DIN:00747131

[Signature]

(Ronak K. Shah)

Director

DIN:03350856

Sungrace Pharma Private Limited
Cash Flow Statement for the year 2022-23

(₹ '000)

Particulars	31.03.2023 Rs.	31.03.2022 Rs.
A. <u>Cash flow from operating activities</u>		
Net profit before taxation, and extraordinary items	4,105.74	4,327.35
<u>Adjustments for:</u>		
Depreciation	176.58	70.83
Interest income	(0.49)	-
Interest expense	1,204.68	1,634.99
Operating profit before working capital changes	5,486.51	6,033.16
<u>Movements in working capital</u>		
(Increase)/Decrease in Trade Receivables	(1,085.92)	4,358.19
(Increase)/Decrease in Inventories	3,140.56	2,574.95
(Increase)/Decrease other Non Current and current assets	187.49	(1,296.22)
(Decrease)/Increase in Trade Payables	(2,147.19)	(3,727.11)
(Decrease)/Increase in Other liabilities/ Provision	(3,378.57)	2,606.09
Cash (used in)/generated from operations	2,202.87	10,549.06
Taxes paid (net of refunds)	(247.41)	(242.06)
Cash flow before extraordinary items	1,955.46	10,307.00
Extraordinary item	-	-
Net cash (used in)/ from operating activities (A)	1,955.46	10,307.00
B. <u>Cash flows from investing activities</u>		
Payments for property, plant and equipment	-	(352.00)
Payments to acquire financial assets	(50.00)	-
Interest received	0.49	-
Net cash (used in)/ from investing activities (B)	(49.51)	(352.00)



Sungrace Pharma Private Limited
Cash Flow Statement for the year 2022-23

(₹ '000)

Particulars	31.03.2023 Rs.	31.03.2022 Rs.
C. Cash flows from financing activities		
Proceeds from issuance of share capital	-	-
Proceeds from borrowings	(605.59)	(8,065.19)
Repayment of borrowings	-	-
Interest paid	(1,204.68)	(1,634.99)
Net cash introduced from /(used in) financing activities (C)	(1,810.27)	(9,700.18)
Net (decrease)/increase in cash & cash equiv. (A+B+C)	95.67	254.81
Cash and cash equivalents at the beginning of the year	1,407.21	1,152.40
Cash and cash equivalents at the end of the year	1,502.88	1,407.21
Components of cash and cash equivalents		
Cash on hand	422.79	421.06
With banks		
- on current account	1,080.09	986.16
	1,502.88	1,407.21

Note:

The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard (Ind AS-7) - Statement of Cash Flow.

As per our report of even date

For, B H MANGAROLIA & CO.

Chartered Accountants

(FRN 105972W)

Bhargava

(P B MANGAROLIA)

Partner

M. No. 124424



UDIN:23124424BGXRCW5995

Place: Ahmedabad

Date: 29.05.2023

For and on behalf of the Board

Sharad B. Shah

(Sharad B. Shah)

Director

DIN:00747131

(Ronak K. Shah)

Director

DIN:03350856

Sungrace Pharma Private Limited

Statement of Changes in Equity for the year ended 31st March, 2023

A. Equity share capital		(₹ '000)
PARTICULARS		Amount Rs.
As at 1 April 2021		260.00
Changes in equity share capital due to prior period errors		-
Restated balance As at 1 April 2021		-
Changes in equity share capital during the year		-
As at 31 March 2022		260.00
Changes in equity share capital due to prior period errors		-
Restated balance As at 1 April 2022		-
Changes in equity share capital during the year		-
As at 31 March 2023		260.00

B. Other Equity				(₹ '000)
PARTICULARS	Securities premium Amount Rs.	Retained Earnings Amount Rs.	Total Amount Rs.	
As at 1 April 2021	2,944.00	4,131.01	7,075.01	
Profit / (Loss) for the year	-	3,212.11	3,212.11	
Other Comprehensive Income / (Loss)	-	-	-	
Total Comprehensive Income for the year	-	3,212.11	3,212.11	
Premium on shares issued during the year	-	-	-	
As at 31 March 2022	2,944.00	7,343.12	10,287.12	
As at 1 April 2022	2,944.00	7,343.12	10,287.12	
Profit / (Loss) for the year	-	3,053.17	3,053.17	
Other Comprehensive Income / (Loss)	-	-	-	
Total Comprehensive Income for the year	-	3,053.17	3,053.17	
Premium on shares issued during the year	-	-	-	
As at 31 March 2023	2,944.00	10,396.29	13,340.29	

As per our report of even date

For, B H MANGAROLIA & CO.

Chartered Accountants

(FRN 105972W)

(P B MANGAROLIA)

Partner

M. No. 124424



UDIN:23124424BGXRCW5995

Place: Ahmedabad

Date: 29.05.2023

For and on behalf of the Board

(Sharad B. Shah)

Director

DIN:00747131

(Ronak K. Shah)

Director

DIN:03350856

01. Company Overview

Sungrace Pharma Private Limited ('the company'), incorporated under the Companies Act, 2013 vide CIN -U24110GJ2019PTC106267 having its registered office at 4 , Madhav Estate, Village - Aslali Taluka - Daskroi, District - Ahmedabad, Ahmedabad-382427 Gujarat and engaged in Dealing in Pharmaceuticals, Drugs, Medicines and allied items.

02. Basis of preparation and Significant accounting policies

2.01 Statement of compliance

The financial statements of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) as per the Companies (Indian Accounting Standards) Rules, 2015 as amended and notified under Section 133 of the Companies Act, 2013 ("the Act") and other relevant provisions of the Act. The financial statements have been prepared on accrual basis under the historical cost convention. The accounting policies adopted in the preparation of the financial statements are consistent with those followed in the previous year.

2.02 Basis of preparation and presentation

The financial statements have been prepared on the historical cost basis except for certain financial instruments that are measured at fair values at the end of each reporting period.

2.03 Use of estimates

The preparation of the financial statements in conformity with Ind AS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from those estimates. The Management believes that the estimates used in preparation of the financial statements are prudent and reasonable. Future results could differ due to these estimates and the differences between the actual results and the estimates are recognised in the periods in which the results are known / materialise.

2.04 Current versus non-current classification

The company presents assets and liabilities in the balance sheet bases on current/non-current classification. An asset is treated as current when it

- expected to be realised or intended to be sold or consumed in normal operating cycle,
- held primarily for the purpose of trading,
- expected to be realised within twelve months after the reporting period, or
- cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve month after the reporting period

All other assets are classified as non-current

A liability is current when it is :

- expected to be settled in normal operating cycle,
- held primarily for the purpose of trading,
- due to be settled within twelve months after the reporting period, or
- there is no unconditional right to defer the settlement of liability for atleast twelve months after the reporting period.



The Company classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities.

The operation cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents. The company has identified twelve months as its operating cycle.

2.05 Property, plant and equipment and other intangible assets

Recognition and measurement:

Items of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses, if any.

Cost of an item of property, plant and equipment comprises its purchase price, including import duties and non-refundable purchase taxes, after deducting trade discounts and rebates, any directly attributable cost of bringing the item to its working condition for its intended use and estimated costs of dismantling and removing the item and restoring the site on which it is located.

Any gain or loss on disposal of an item of property, plant and equipment is recognised in statement of profit or loss.

Depreciation and amortisation:

Depreciation, on fixed assets, based on useful life of the assets as prescribed in Schedule II to the Companies Act, 2013, on Written Down Value (WDV) method. Depreciation on additions during the year is provided on prorata time basis.

2.06 Inventories

Inventories are valued at the lower of cost and the net realisable value after providing for obsolescence and other losses, where considered necessary. Cost of inventory includes cost of purchase and other costs incurred in bringing the inventories to their present location and condition. The basis of determining cost for stock in trade and other products are determined on First in first out (FIFO) method and are net of input tax credit.

2.07 Cash and cash equivalents (for purposes of Cash Flow Statement)

Cash comprises cash on hand and demand deposits with banks. Cash equivalents are short-term balances (with an original maturity of three months or less from the date of acquisition), highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value.

2.08 Cash flow statement

Cash flows are reported using the indirect method, whereby profit / (loss) before extraordinary items and tax is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregated based on the available information.



2.09 Revenue recognition

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured.

Sale of goods

Sales are recognised, net of returns and trade discounts, on transfer of significant risks and rewards of ownership to the buyer, which generally coincides with the delivery of goods to customers.

Other income

Interest income is accounted on accrual basis.
All other income is recognised on accrual basis.

2.10 Employee benefits

Short Term Employee Benefits

Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided. A liability is recognised for the amount expected to be paid if the Company has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee, and the amount of obligation can be estimated reliably.

Defined contribution plans

The Company's contribution to provident fund is considered as defined contribution plans and is charged as an expense as they fall due based on the amount of contribution required to be made.

Defined benefit plans

Gratuity:

Gratuity liability is a defined benefit obligation and is computed on the basis of an actuarial valuation by an actuary appointed for the purpose as per projected unit credit method at the end of each financial year. The liability or asset recognized in the Standalone Balance Sheet in respect of defined benefit gratuity plan, is the present value of the defined benefit obligation at the end of the reporting period less the fair value of plan assets. The liability so provided is represented by creation of separate fund and is used to meet the liability as and when it become due for payment in future. Any shortfall in the value of assets over the defined benefit obligation is recognized as a liability with a corresponding charge to the Standalone Statement of Profit and Loss.

The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows with reference to market yields at the end of the reporting period on government bonds that have terms approximating to the terms of the related obligation.

The net interest cost is calculated by applying the discount rate at the beginning of the period to the net balance of the defined benefit obligation and the fair value of plan assets. This cost is included in employee benefit expense in the Standalone Statement of Profit and Loss.

Re-measurement gains and losses arising from experience adjustments and changes in actuarial assumptions are recognized in the period in which they occur directly in other comprehensive income. They are included in retained earnings in the Statement of changes in equity and in the Standalone Balance Sheet.



Changes in the present value of the defined benefit obligation resulting from plan amendments or curtailments are recognized immediately in profit or loss as past service cost.

2.11 Borrowing costs

Borrowing costs include interest, amortisation of ancillary costs incurred and exchange differences arising from foreign currency borrowings to the extent they are regarded as an adjustment to the interest cost. Costs in connection with the borrowing of funds to the extent not directly related to the acquisition of qualifying assets are charged to the Statement of Profit and Loss over the tenure of the loan. Borrowing costs, allocated to and utilised for qualifying assets, pertaining to the period from commencement of activities relating to construction / development of the qualifying asset upto the date of capitalisation of such asset is added to the cost of the assets. Capitalisation of borrowing costs is suspended and charged to the Statement of Profit and Loss during extended periods when active development activity on the qualifying assets is interrupted.

2.12 Earnings per share

Basic earnings per share is computed by dividing the profit / (loss) after tax (including the post tax effect of extraordinary items, if any) by the weighted average number of equity shares outstanding during the year.

2.13 Taxes on income

Current tax:

The tax currently payable is based on taxable profit for the year. Taxable profit differs from 'profit before tax' as reported in the statement of profit and loss because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The Company's current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax:

Deferred tax is recognised on temporary differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable temporary differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilised. Such deferred tax assets and liabilities are not recognised if the temporary difference arises from the initial recognition (other than in a business combination) of assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax liabilities and assets are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.



Sungrace Pharma Private Limited
Notes forming part of the financial statements (2022-23)

The measurement of deferred tax liabilities and assets reflects the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.

2.14 Contingent liabilities

A contingent liability exists when there is a possible but not probable obligation, or a present obligation that may, but probably will not, require an outflow of resources, or a present obligation whose amount cannot be estimated reliably. Contingent liabilities do not warrant provisions, but are disclosed unless the possibility of outflow of resources is remote. Contingent assets are disclosed in the financial statements if an inflow of economic benefits is probable.

2.15 Contingent assets

Contingent assets are disclosed where an inflow of economic benefits is probable.



Sungrace Pharma Private Limited

Notes forming part of the financial statements (2022-23)

Non-current assets

03. Property, Plant and Equipment

(₹ '000)

Particulars	Office Equipments	Computers	Total
	Rs.	Rs.	Rs.
<u>Gross Carrying Amount</u>			
At 1 April 2021	-	12.51	12.51
Additions	52.40	299.60	352.00
Disposals	-	-	-
At 31 March 2022	52.40	312.11	364.51
Additions	-	-	-
Disposals	-	-	-
At 31 March 2023	52.40	312.11	364.51

Depreciation and impairment

At 1 April 2021	-	3.72	3.72
Depreciation charge for the year	16.15	54.68	70.83
Disposals	-	-	-
At 31 March 2022	16.15	58.40	74.55
Depreciation charge for the year	16.34	160.24	176.58
Disposals	-	-	-
At 31 March 2023	32.49	218.64	251.13
Net book value			
At 31 March 2023	19.91	93.47	113.38
At 31 March 2022	36.25	253.71	289.96

Non-current assets

Financial Assets

04. Investments

(₹ '000)

Particulars	As at 31.03.2023 Rs.	As at 31.03.2022 Rs.
Investment in equity instruments (Unquoted) 2,000 Shares (Prev. year 1,000 shares) of Rs. 50/- each fully paid up in The Ahmedabad Mercantile Co. Op. Bank Limited	100.01	50.01
Total Investments	100.01	50.01

Non-current assets

05. Deferred Tax Assets (Net)

(₹ '000)

Particulars	As at 31.03.2023 Rs.	As at 31.03.2022 Rs.
Deferred tax assets/(Liabilities) on account of Property, Plant and Equipment	107.50	0.07
Employee Benefits (Defined benefit obligations)		
Total Deferred Tax Assets (Net)	107.50	0.07



Sungrace Pharma Private Limited
Notes forming part of the financial statements (2022-23)

<i>Movement of Deferred Tax Assets/(Liabilities)</i>		(₹ '000)	
Particulars	As at	As at	
	31.03.2023	31.03.2022	
	Rs.	Rs.	
<u><i>Property, Plant and Equipment</i></u>			
Opening Balance	0.07	0.31	
Total Reversible Timing Difference in books maintained as per Companies Act, 2013			
Depreciation as per Companies Act, 2013	176.58	70.83	
Total Reversible Timing Difference in books maintained as per Income Tax Act, 1961			
Depreciation as per Income Tax Act, 2013	104.96	71.78	
Net Timing Difference	71.63	(0.96)	
Deferred tax assets/(Liabilities) recognised in statement of Profit & Loss	18.03	(0.24)	
Closing Balance	18.10	0.07	
<u><i>Employee Benefits (Defined benefit obligations)</i></u>			
Opening Balance	-	-	
Total Reversible Timing Difference in books maintained as per Companies Act, 2013			
Gratuity Exps as per Companies Act, 2013	355.22	-	
Total Reversible Timing Difference in books maintained as per Income Tax Act, 1961			
Gratuity Exps as per Income Tax Act, 2013	-	-	
Net Timing Difference	355.22	-	
Deferred tax assets/(Liabilities) recognised in statement of Profit & Loss	89.41	-	
Closing Balance	89.41	-	
Total	107.50	0.07	

06. Other Non-current Assets

		(₹ '000)	
Particulars	As at	As at	
	31.03.2023	31.03.2022	
	Rs.	Rs.	
Capital advances	2,250.00	1,750.00	
Total Other Non-current Assets	2,250.00	1,750.00	



Sungrace Pharma Private Limited
Notes forming part of the financial statements (2022-23)

Current assets

07. Inventories

(₹ '000)

Particulars	As at 31.03.2023 Rs.	As at 31.03.2022 Rs.
Stock-in-trade (acquired for trading)	12,332.28	15,472.84
Total Inventories	12,332.28	15,472.84

Current assets

Financial Assets

08. Trade receivables

(₹ '000)

Particulars	As at 31.03.2023 Rs.	As at 31.03.2022 Rs.
Trade receivables Unsecured, considered good	20,676.45	19,590.53
Less: Allowance for doubtful debts	-	-
Total Trade receivables	20,676.45	19,590.53

Trade Receivables ageing schedule - As at 31.03.2023

(₹ '000)

Particulars	Outstanding for following periods from due date of payment						Total
	Not Due	Less than 6 months	6 months - 1 year	1-2 year	2-3 year	More than 3 years	
Undisputed Trade receivables - considered good	10,949.04	7,226.25	472.08	1,189.88	839.21	-	20,676.45
Undisputed Trade Receivables - which have significant increase in credit risk	-	-	-	-	-	-	-
Undisputed Trade Receivables - credit impaired	-	-	-	-	-	-	-
Disputed Trade Receivables- considered good	-	-	-	-	-	-	-
Disputed Trade Receivables - which have significant increase in credit risk	-	-	-	-	-	-	-
Disputed Trade Receivables - credit impaired	-	-	-	-	-	-	-
	10,949.04	7,226.25	472.08	1,189.88	839.21	-	20,676.45



Sungrace Pharma Private Limited
Notes forming part of the financial statements (2022-23)

Trade Receivables ageing schedule - As at 31.03.2022							(₹ '000)
Particulars	Outstanding for following periods from due date of payment						Total
	Not Due	Less than 6 months	6 months - 1 year	1-2 year	2-3 year	More than 3 years	
Undisputed Trade receivables							
- considered good	15,667.89	1,935.46	1,730.86	256.33	-	-	19,590.53
Undisputed Trade Receivables							
- which have significant increase in credit risk	-	-	-	-	-	-	-
Undisputed Trade Receivables							
- credit impaired	-	-	-	-	-	-	-
Disputed Trade Receivables-							
considered good	-	-	-	-	-	-	-
Disputed Trade Receivables -							
which have significant increase in credit risk	-	-	-	-	-	-	-
Disputed Trade Receivables -							
credit impaired	-	-	-	-	-	-	-
	15,667.89	1,935.46	1,730.86	256.33	-	-	19,590.53

Current assets

Financial Assets

09. Cash and Cash Equivalents

(₹ '000)

Particulars	As at	As at
	31.03.2023	31.03.2022
	Rs.	Rs.
<i>Cash and cash equivalents</i>		
Balances with banks		
-Current accounts	1,080.09	986.16
Cash on hand	422.79	421.06
Total Cash and Cash Equivalents	1,502.88	1,407.21

10. Other Current Assets

(₹ '000)

Particulars	As at	As at
	31.03.2023	31.03.2022
	Rs.	Rs.
Advances to Suppliers of Goods and Services	110.76	718.87
Employee Advances	-	1.72
Prepaid Expenses	2.00	7.89
Balances with government authorities	1.06	79.43
Others	12.60	6.00
Total Other Current Assets	126.42	813.91



Sungrace Pharma Private Limited
Notes forming part of the financial statements (2022-23)

11. Equity share capital

(₹ '000)

Particulars	As at 31.03.2023		As at 31.03.2022	
	Number	Rs.	Number	Rs.
<u>Authorised</u>				
Equity shares of Rs. 10 each	100,000	1,000.00	100,000	1,000.00
Total Share Capital	100,000	1,000.00	100,000	1,000.00
<u>Issued</u>				
<u>Subscribed and fully paid up</u>				
Equity shares of Rs. 10 each	26,000	260.00	26,000	260.00
Total Share Capital	26,000	260.00	26,000	260.00
<u>Reconciliation of Share Capital</u>				
<u>Equity shares of Rs. 10 each</u>				
i outstanding at the beginning of the year	26,000	260.00	26,000	260.00
ii Issued during the year	-	-	-	-
iii bought back during the year	-	-	-	-
iv outstanding at the end of the year	26,000	260.00	26,000	260.00

Rights, preferences and restrictions attached to Equity shares

The Company has only one class of shares referred to as equity shares having a par value of Rs 10 each.

Each shareholder is eligible for one vote per share held. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting, except in case of interim dividend.

In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the Company after distribution of all preferential amounts, in proportion to their shareholding.

Details of shares held by each shareholder holding more than 5% shares

Equity shares of Rs. 10 each

Sr. No.	Name of Shareholder	As at 31.03.2023		As at 31.03.2022	
		Number	%	Number	%
1	Medico Intercontinental Limited	25,999	99.996	25,999	99.996

Disclosure of Shareholding of Promoters

Disclosure of Shareholding of Promoters - As at 31.03.2023

Sr. No.	Promoter name	As at 31.03.2023		As at 31.03.2022		% Change during the year
		Number	%	Number	%	
1	Medico Intercontinental Limited	25,999	99.996	25,999	99.996	-
	Total	25,999	99.996	25,999	99.996	

Disclosure of Shareholding of Promoters - As at 31.03.2022

Sr. No.	Promoter name	As at 31.03.2022		As at 31.03.2021		% Change during the year
		Number	%	Number	%	
1	Medico Intercontinental Limited	25,999	99.996	25,999	99.990	-
	Total	25,999	99.996	25,999	99.990	



Sungrace Pharma Private Limited

Notes forming part of the financial statements (2022-23)

12. Other equity

(₹ '000)

Particulars	As at 31.03.2023 Rs.	As at 31.03.2022 Rs.
<u>Securities premium account</u>		
Opening balance	2,944.00	2,944.00
Add : Premium on shares issued during the year	-	-
Less : Utilised during the year		
Issuing bonus shares	-	-
Closing balance	2,944.00	2,944.00
<u>Retained Earnings</u>		
Opening balance	7,343.12	4,131.01
Add: Profit / (Loss) for the year as per the Statement of Profit and Loss	3,053.17	3,212.11
Closing balance	10,396.29	7,343.12
Total Other equity	13,340.29	10,287.12

Non-current Liabilities

Financial Liabilities

13. Borrowings

(₹ '000)

Particulars	As at 31.03.2023 Rs.	As at 31.03.2022 Rs.
<u>Unsecured</u>		
Loans from Directors	230.40	1,304.55
Other Borrowings	-	-
	230.40	1,304.55
Total Borrowings	230.40	1,304.55

Non-current Liabilities

14. Provisions

Particulars	As at 31.03.2023 Rs.	As at 31.03.2022 Rs.
Provision for employee benefits (Gratuity)	354.26	-
Provision - Others	-	-
Total Provisions	354.26	-



Sungrace Pharma Private Limited
Notes forming part of the financial statements (2022-23)

Current Liabilities
Financial Liabilities

15. Borrowings

(₹ '000)

Particulars	As at 31.03.2023 Rs.	As at 31.03.2022 Rs.
<u>Secured</u>		
Loans repayable on demand		
<i>From Banks (Working Capital)</i>		
The Ahmedabad Mercantile Co Op bank Limited	12,511.07	12,042.52
<u>Primary Security</u>		
Secured by hypothecation of stocks and book debts / receivables of the Company		
<u>Collateral Security</u>		
1. Commercial Property owned by Smt. Tanvi Shah situated at Godown No 59, Skyline Infra Hub, B/s Claris, Matoda Patia, Ahmedabad		
2. Commercial Property owned by M/s Medico Healthcare situated at 402-403, Aditraj Arcade, Anandnagar Road, Staellite, Ahmedabad		
	12,511.07	12,042.52
Total Borrowings	12,511.07	12,042.52

Current Liabilities
Financial Liabilities

16. Trade payables

(₹ '000)

Particulars	As at 31.03.2023 Rs.	As at 31.03.2022 Rs.
Trade payable - Micro and small enterprises	2,859.93	6,724.29
Trade payable - Other than micro and small enterprises	5,848.58	4,131.42
Total Trade payables	8,708.51	10,855.71

Disclosures required under Section 22 of the Micro, Small and Medium Enterprises Development Act, 2006

This information has been determined to the extent such parties have been identified on the basis of information available with the Company.

Particulars	As at 31.03.2023 Rs.	As at 31.03.2022 Rs.
a) Principal amount remaining unpaid to any supplier as at the end of the accounting year	2,859.93	6,724.29
b) Interest paid by the Company in terms of Section 16 of the Micro, Small and Medium Enterprises Development Act, 2006, along with the amount of the payment made to the supplier beyond the appointed day	-	-
c) Interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the period) but without adding interest specified under the Micro, Small and Medium Enterprises Act, 2006	-	-



Sungrace Pharma Private Limited

Notes forming part of the financial statements (2022-23)

d) Interest accrued and remaining unpaid	-	-
e) Interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprises	-	-

Trade Payables ageing schedule - As at 31.03.2023

(₹ '000)

Particulars	Outstanding for following periods from due date of payment					Total
	Not Due	Less than 1 year	1-2 year	2-3 year	More than 3 years	
MSME	2,329.98	529.96	-	-	-	2,859.93
Others	2,425.37	1,025.65	2,397.55	-	-	5,848.58
Disputed dues - MSME	-	-	-	-	-	-
Disputed dues - Others	-	-	-	-	-	-
Total	4,755.35	1,555.61	2,397.55	-	-	8,708.51

Trade Payables ageing schedule - As at 31.03.2022

(₹ '000)

Particulars	Outstanding for following periods from due date of payment					Total
	Not Due	Less than 1 year	1-2 year	2-3 year	More than 3 years	
MSME	3,924.19	2,800.10	-	-	-	6,724.29
Others	1,433.86	2,697.55	-	-	-	4,131.42
Disputed dues - MSME	-	-	-	-	-	-
Disputed dues - Others	-	-	-	-	-	-
Total	5,358.05	5,497.65	-	-	-	10,855.71

Current Liabilities

17. Provisions

Particulars	As at 31.03.2023	As at 31.03.2022
	Rs.	Rs.
Provision for employee benefits (Gratuity)	0.96	-
Provision - Others	-	-
Total Provisions	0.96	-

Current Liabilities

18. Other current liabilities

(₹ '000)

Particulars	As at 31.03.2023	As at 31.03.2022
	Rs.	Rs.
Statutory Liabilities	515.99	160.50
Payables for Expenses	880.93	3,785.82
Advances from customers	140.07	209.45
Total Other current liabilities	1,536.98	4,155.77



Sungrace Pharma Private Limited
Notes forming part of the financial statements (2022-23)

Current Liabilities

19. Current Tax Liabilities (net)

(₹ '000)

Particulars	As at	As at
	31.03.2023	31.03.2022
	Rs.	Rs.
Current Income Tax Liabilities (net of Taxes Paid)	266.45	468.87
Total Current Tax Assets (Net)	266.45	468.87



Sungrace Pharma Private Limited

Notes forming part of the financial statements (2022-23)

20. Revenue from operations

(₹ '000)

Particulars	As at 31.03.2023 Rs.	As at 31.03.2022 Rs.
Revenue from Sale of Products - Stock-in-trade	53,046.55	86,188.32
Revenue from Sale of services	-	-
Other operating revenues	-	-
Total Revenue from operations	53,046.55	86,188.32

21. Other income

(₹ '000)

Particulars	As at 31.03.2023 Rs.	As at 31.03.2022 Rs.
Interest income	0.49	-
Dividend income	6.00	4.00
Other non-operating income (net of expenses directly attributable to such income)	1,459.88	180.00
Total Other income	1,466.37	184.00

Interest income comprises:

Interest on income tax refund

	0.49	-
Total	0.49	-

Particulars	As at 31.03.2023 Rs.	As at 31.03.2022 Rs.
Other non-operating income comprises:		
Commission Income	1,459.88	180.00
Total	1,459.88	180.00

22. Purchases of stock-in-trade

(₹ '000)

Particulars	As at 31.03.2023 Rs.	As at 31.03.2022 Rs.
Purchases - Stock-in-trade	36,511.85	64,536.27
Total Purchases of stock-in-trade	36,511.85	64,536.27



Sungrace Pharma Private Limited

Notes forming part of the financial statements (2022-23)

**23. Changes in inventories of finished goods,
work-in-progress and stock-in-trade**

(₹ '000)

Particulars	As at 31.03.2023 Rs.	As at 31.03.2022 Rs.
Inventories at the end of the year:		
Stock-in-trade (acquired for trading)	12,332.28	15,472.84
	12,332.28	15,472.84
Inventories at the beginning of the year:		
Stock-in-trade (acquired for trading)	15,472.84	18,047.79
	15,472.84	18,047.79
Net (increase) / decrease in inventories	3,140.56	2,574.95

24. Employee benefits expense

(₹ '000)

Particulars	As at 31.03.2023 Rs.	As at 31.03.2022 Rs.
Salaries	4,919.57	4,385.22
Contributions to PF, ESI and other funds	154.42	137.02
Gratuity Expenses	355.22	-
Total Employee benefits expense	5,429.21	4,522.24

25. Finance costs

(₹ '000)

Particulars	As at 31.03.2023 Rs.	As at 31.03.2022 Rs.
Interest expense on		
Borrowings	1,174.12	1,613.77
Interest on delayed payment of statutory dues	4.62	0.28
Other borrowing costs	25.95	20.95
Total Finance costs	1,204.68	1,634.99

26. Depreciation and amortisation expense

(₹ '000)

Particulars	As at 31.03.2023 Rs.	As at 31.03.2022 Rs.
Depreciation on property, plant and equipment	176.58	70.83
Amortisation on Intangible assets	-	-
Total Depreciation and amortisation expense	176.58	70.83



Sungrace Pharma Private Limited

Notes forming part of the financial statements (2022-23)

27. Other expenses

(₹ '000)

Particulars	As at 31.03.2023 Rs.	As at 31.03.2022 Rs.
Freight Exps.	255.29	387.63
Cylinder Charges	4.80	2.54
Rent	876.00	870.00
Repairs and maintenance - Others	59.81	92.39
Insurance	47.54	53.86
Rates and taxes	26.91	52.01
Communication Exps.	200.96	311.33
Travelling and conveyance	364.77	282.32
Printing and stationery	17.37	20.30
Legal and professional	155.20	140.15
Payments to auditors	41.50	40.00
Electricity Exps	66.61	51.01
Other Miscellaneous expenses	147.26	109.47
Sales commission	164.07	2,555.92
Advertisement Exps.	75.30	20.25
Business promotion	1,134.37	3,384.78
Freight Outward Exps.	306.55	331.74
Total Other expenses	3,944.31	8,705.69

Particulars	As at 31.03.2023 Rs.	As at 31.03.2022 Rs.
<i>Payments to the auditors comprises</i>		
As auditors	41.50	40.00
For taxation matters	-	-
Total	41.50	40.00

28. Earning Per Share

(₹ '000)

Particulars	As at 31.03.2023 Rs.	As at 31.03.2022 Rs.
Earnings per share		
Profit/(Loss) attributable to equity holders of the Company	3,053.17	3,212.11
Weighted average number of equity shares	26,000	26,000
Basic Earnings Per Share (in ₹)	117.43	123.54
Diluted Earnings Per Share (in ₹)	117.43	123.54

The Company does not have any outstanding dilutive potential equity shares. Consequently the basic and dilutive earning per share of the Company remain the same.



Sungrace Pharma Private Limited

Notes forming part of the financial statements (2022-23)

29. Segment Reporting

The Company's business activity falls within a single primary segment viz., Dealing in Pharmaceuticals. As such there are no separate reportable segments.

30. Employee Benefits

A. Defined Contribution Plan

Provident fund

The provident fund and the state defined contribution plans are operated by the Regional Provident Fund Commissioner. Under the scheme, the Company is required to contribute a specified percentage of payroll cost to the retirement benefit scheme to fund the benefits. These funds are recognized by the income tax authorities. The contribution of the Company to the provident fund and other contribution plans for all employees is charged to the Standalone Statement of Profit and Loss.

The Company has recognised the following amounts in the Statement of Profit and Loss under Contribution to Provident Funds as under:

Particulars	(₹ '000)	
	As at	As at
	31.03.2023	31.03.2022
	Rs.	Rs.
Employer's contribution to Provident Fund	154.42	137.02
Total	154.42	137.02

B. Defined benefit Plan

Retirement Gratuity

The Gratuity Plan is governed by the Payment of Gratuity Act, 1972. Under the Act, employee who has completed five years of service is entitled to specific benefit. The level of benefits provided depends on the member's length of service and salary at retirement age. The following tables summarise the components of net benefit expense recognised in the Statement of Profit and Loss and the funded status and amounts recognised in the Balance Sheet for the respective plans:

Particulars	(₹ '000)	
	As at	As at
	31.03.2023	31.03.2022
	Rs.	Rs.
<u>Actuarial Assumptions</u>		
Expected Return on Plan Assets	N.A.	-
Rate of Discounting	7.47%	-
Rate of Salary Increase	7.00%	-
Rate of Employee Turnover	7.00%	-
Mortality Rate During Employment	Indian Assured Lives Mortality 2012-14 (Urban)	-



Sungrace Pharma Private Limited

Notes forming part of the financial statements (2022-23)

Particulars	(₹ '000)	
	As at	As at
	31.03.2023	31.03.2022
	Rs.	Rs.
<u>Table Showing Change in the Present Value of Defined Benefit Obligation</u>		
Present Value of Benefit Obligation at the Beginning of the Period	-	-
Interest Cost	-	-
Current Service Cost	355.22	-
Past Service Cost	-	-
Liability Transferred In/ Acquisitions	-	-
(Liability Transferred Out/ Divestments)	-	-
(Gains)/ Losses on Curtailment	-	-
(Liabilities Extinguished on Settlement)	-	-
(Benefit Paid Directly by the Employer)	-	-
(Benefit Paid From the Fund)	-	-
The Effect Of Changes in Foreign Exchange Rates	-	-
Actuarial (Gains)/Losses on Obligations - Due to Change in Demographic Assumptions	-	-
Actuarial (Gains)/Losses on Obligations - Due to Change in Financial Assumptions	-	-
Actuarial (Gains)/Losses on Obligations - Due to Experience	-	-
Present Value of Benefit Obligation at the End of the Period	355.22	-

Particulars	(₹ '000)	
	As at	As at
	31.03.2023	31.03.2022
	Rs.	Rs.
<u>Table Showing Change in the Fair Value of Plan Assets</u>		
Fair Value of Plan Assets at the Beginning of the Period	-	-
Interest Income	-	-
Contributions by the Employer	-	-
Expected Contributions by the Employees	-	-
Assets Transferred In/Acquisitions	-	-
(Assets Transferred Out/ Divestments)	-	-
(Benefit Paid from the Fund)	-	-
(Assets Distributed on Settlements)	-	-
Effects of Asset Ceiling	-	-
The Effect of Changes In Foreign Exchange Rates	-	-
Return on Plan Assets, Excluding Interest Income	-	-
Fair Value of Plan Assets at the End of the Period	-	-

Particulars	(₹ '000)	
	As at	As at
	31.03.2023	31.03.2022
	Rs.	Rs.
<u>Amount Recognized in the Balance Sheet</u>		
(Present Value of Benefit Obligation at the end of the Period)	(355.22)	-
Fair Value of Plan Assets at the end of the Period	-	-
Funded Status (Surplus/ (Deficit))	(355.22)	-
Net (Liability)/Asset Recognized in the Balance Sheet	(355.22)	-



Sungrace Pharma Private Limited

Notes forming part of the financial statements (2022-23)

(₹ '000)

Particulars	As at 31.03.2023 Rs.	As at 31.03.2022 Rs.
<u>Net Interest Cost for Current Period</u>		
Present Value of Benefit Obligation at the Beginning of the Period	-	-
(Fair Value of Plan Assets at the Beginning of the Period)	-	-
Net Liability/(Asset) at the Beginning	-	-
Interest Cost	-	-
(Interest Income)	-	-
Net Interest Cost for Current Period	-	-

(₹ '000)

Particulars	As at 31.03.2023 Rs.	As at 31.03.2022 Rs.
<u>Expenses Recognized in the Statement of Profit or Loss for Current Period</u>		
Current Service Cost	355.22	-
Net Interest Cost	-	-
Past Service Cost	-	-
(Expected Contributions by the Employees)	-	-
(Gains)/Losses on Curtailments And Settlements	-	-
Net Effect of Changes in Foreign Exchange Rates	-	-
Expenses Recognized	355.22	-

(₹ '000)

Particulars	As at 31.03.2023 Rs.	As at 31.03.2022 Rs.
<u>Expenses Recognized in the Other Comprehensive Income (OCI) for Current Period</u>		
Actuarial (Gains)/Losses on Obligation For the Period	-	-
Return on Plan Assets, Excluding Interest Income	-	-
Change in Asset Ceiling	-	-
Net (Income)/Expense For the Period Recognized in OCI	-	-

(₹ '000)

Particulars	As at 31.03.2023 Rs.	As at 31.03.2022 Rs.
<u>Balance Sheet Reconciliation</u>		
Opening Net Liability	-	-
Expenses Recognized in Statement of Profit or Loss	355.22	-
Expenses Recognized in OCI	-	-
Net Liability/(Asset) Transfer In	-	-
Net (Liability)/Asset Transfer Out	-	-
(Benefit Paid Directly by the Employer)	-	-
(Employer's Contribution)	-	-
Net Liability/(Asset) Recognized in the Balance Sheet	355.22	-



Sungrace Pharma Private Limited
Notes forming part of the financial statements (2022-23)

(₹ '000)

Particulars	As at 31.03.2023 Rs.	As at 31.03.2022 Rs.
<u>Category of Assets</u>		
Government of India Assets	-	-
State Government Securities	-	-
Special Deposits Scheme	-	-
Debt Instruments	-	-
Corporate Bonds	-	-
Cash And Cash Equivalents	-	-
Insurance fund	-	-
Asset-Backed Securities	-	-
Structured Debt	-	-
Other	-	-
Total	-	-

(₹ '000)

Particulars	As at 31.03.2023 Rs.	As at 31.03.2022 Rs.
<u>Other Details</u>		
No of Members in Service	14	-
Per Month Salary For Members in Service	188.60	-
Weighted Average Duration of the Defined Benefit Obligation	12.03	-
Average Expected Future Service	11	-
Defined Benefit Obligation (DBO) - Total	355.22	-
Defined Benefit Obligation (DBO) - Due but Not Paid	-	-
Expected Contribution in the Next Year	-	-

(₹ '000)

Particulars	As at 31.03.2023 Rs.	As at 31.03.2022 Rs.
<u>Net Interest Cost for Next Year</u>		
Present Value of Benefit Obligation at the End of the Period	355.22	-
(Fair Value of Plan Assets at the End of the Period)	-	-
Net Liability/(Asset) at the End of the Period	355.22	-
Interest Cost	26.54	-
(Interest Income)	-	-
Net Interest Cost for Next Year	26.54	-



Sungrace Pharma Private Limited

Notes forming part of the financial statements (2022-23)

(₹ '000)

Particulars	As at 31.03.2023 Rs.	As at 31.03.2022 Rs.
<u>Maturity Analysis of the Benefit Payments</u>		
Projected Benefits Payable in Future Years From the Date of Reporting		
1st Following Year	0.96	-
2nd Following Year	27.08	-
3rd Following Year	26.94	-
4th Following Year	28.86	-
5th Following Year	28.71	-
Sum of Years 6 To 10	184.66	-
Sum of Years 11 and above	709.22	-

(₹ '000)

Particulars	As at 31.03.2023 Rs.	As at 31.03.2022 Rs.
<u>Sensitivity Analysis</u>		
Defined Benefit Obligation on Current Assumptions	355.22	-
Delta Effect of +1% Change in Rate of Discounting	(33.47)	-
Delta Effect of -1% Change in Rate of Discounting	39.98	-
Delta Effect of +1% Change in Rate of Salary Increase	39.76	-
Delta Effect of -1% Change in Rate of Salary Increase	(33.89)	-
Delta Effect of +1% Change in Rate of Employee Turnover	(2.82)	-
Delta Effect of -1% Change in Rate of Employee Turnover	2.55	-

The sensitivity analysis have been determined based on reasonably possible changes of the respective assumptions occurring at the end of the reporting period, while holding all other assumptions constant.

The sensitivity analysis presented above may not be representative of the actual change in the Defined Benefit Obligation as it is unlikely that the change in assumptions would occur in isolation of one another as some of the assumptions may be correlated.

Furthermore, in presenting the above sensitivity analysis, the present value of the Defined Benefit Obligation has been calculated using the projected unit credit method at the end of the reporting period, which is the same method as applied in calculating the Defined Benefit Obligation as recognised in the balance sheet.

Notes

- Gratuity is payable as per entity's scheme as detailed in the report.
- Actuarial gains/losses are recognized in the period of occurrence under Other Comprehensive Income (OCI). All above reported figures of OCI are gross of taxation.
- Since it is the first year of the company's valuation, we have considered the Current Service Cost to be the same as the Defined Benefit Obligation.
- Salary escalation & attrition rate are considered as advised by the entity; they appear to be in line with the industry practice considering promotion and demand & supply of the employees.
- Maturity Analysis of Benefit Payments is undiscounted cashflows considering future salary, attrition & death in respective year for members as mentioned above.



Sungrace Pharma Private Limited

Notes forming part of the financial statements (2022-23)

- Average Expected Future Service represents Estimated Term of Post - Employment Benefit Obligation.
- Weighted Average Duration of the Defined Benefit Obligation is the weighted average of cash flow timing, where weights are derived from the present value of each cash flow to the total present value.
- Any benefit payment and contribution to plan assets is considered to occur at the end of the period to depict liability and fund movement in the disclosures.

Qualitative Disclosures

Characteristics of defined benefit plan

The Entity has a defined benefit gratuity plan in India (unfunded). The Entity's defined benefit gratuity plan is a final salary plan for employees.

Gratuity is paid from entity as and when it becomes due and is paid as per entity scheme for Gratuity.

Risks associated with defined benefit plan

Gratuity is a defined benefit plan and entity is exposed to the Following Risks:

Interest rate risk: A fall in the discount rate which is linked to the G.Sec. Rate will increase the present value of the liability requiring higher provision.

Salary Risk: The present value of the defined benefit plan liability is calculated by reference to the future salaries of members. As such, an increase in the salary of the members more than assumed level will increase the plan's liability.

Asset Liability Matching Risk: The plan faces the ALM risk as to the matching cash flow. Entity has to manage pay-out based on pay as you go basis from own funds.

Mortality risk: Since the benefits under the plan is not payable for life time and payable till retirement age only, plan does not have any longevity risk.

- Gratuity plan is unfunded.

31. Related party transactions

a Related parties where control exists

i. Holding Company

- Medico Intercontinental Limited

b Other Related parties (where transaction have taken place during the year or previous year)

i. Fellow Subsidiary companies

- Ritz Formulations Private Limited
- Evagrace Pharma Private Limited
- Azillian Healthcare Private Limited



Sungrace Pharma Private Limited

Notes forming part of the financial statements (2022-23)

ii. Enterprises owned or significantly influenced by key management personnel or their relatives

- Sungrace Pharma
- Oxford Pharma
- Kingston Café
- Kingston Infracon
- Flora Marketing

c. Key management personnel (KMP) and their Relativesi. Directors

- Sharad B. Shah
- Ronak K. Shah
- Samir D. Shah

ii. Relatives of Directors

- Khushboo R. Shah

Transactions with related parties

(₹ '000)

Particulars	As at 31.03.2023 Rs.	As at 31.03.2022 Rs.
- <u>Holding Company</u>		
- <u>Purchases</u>		
Medico Intercontinental Limited	5,291.56	25,308.24
- <u>Sales</u>		
Medico Intercontinental Limited	796.27	2,498.43
- <u>Fellow Subsidiary companies</u>		
- <u>Purchases</u>		
Ritz Formulations Private Limited	1,238.27	1,598.38
Evagrace Pharma Private Limited	1,592.71	1,096.88
Azillian Healthcare Private Limited	158.44	782.99
Total	2,989.42	3,478.25
- <u>Sales</u>		
Ritz Formulations Private Limited	1,500.04	1,560.59
Evagrace Pharma Private Limited	801.60	650.77
Azillian Healthcare Private Limited	583.46	1,390.36
Total	2,885.10	3,601.72



Sungrace Pharma Private Limited

Notes forming part of the financial statements (2022-23)

- Enterprises owned or significantly influenced by key management personnel or their relatives

- Purchases

Oxford Pharma

	11,606.62	10,475.86
Total	11,606.62	10,475.86

- Sales Promotion Exps.

Kingston Café

Kingston Infracon

	-	137.55
	-	1,045.00
Total	-	1,182.55

- Rent Exps.

Flora Marketing

Sungrace Pharma

	480.00	480.00
	120.00	120.00
Total	600.00	600.00

- Key management personnel (Directors) and their Relatives

- Salary

Sharad B. Shah

Ronak K. Shah

Khushboo R. Shah

	636.84	602.58
	927.42	805.65
	263.71	228.69
Total	1,827.97	1,636.92

- Interest Exps.

Sharad B. Shah

Ronak K. Shah

	87.10	456.29
	18.36	101.07
Total	105.46	557.35

- Loans Received

Ronak K. Shah

	-	1,175.00
Total	-	1,175.00

- Loans Repayment

Sharad B. Shah

Ronak K. Shah

	854.46	6,099.46
	314.60	2,604.85
Total	1,169.06	8,704.31

Outstanding balances

(₹ '000)

Particulars

As at

As at

31.03.2023

31.03.2022

Rs.

Rs.

- Holding Company

- Trade Payable

Medico Intercontinental Limited

1,774.10	4,380.70
----------	----------

- Fellow Subsidiary companies

- Trade Payable

Evagrace Pharma Private Limited

678.73	401.97
Total	678.73



Sungrace Pharma Private Limited

Notes forming part of the financial statements (2022-23)

- <u>Trade receivables</u>		
Ritz Formulations Private Limited	89.68	70.77
Azillian Healthcare Private Limited	20.11	12.81
Total	109.79	83.57
- <u>Enterprises owned or significantly influenced by key management personnel or their relatives</u>		
- <u>Trade Payable</u>		
Oxford Pharma	1,404.51	(36.59)
- <u>Trade receivables</u>		
Sungrace Pharma	-	(27.10)
Total	-	(27.10)
- <u>Key management personnel (Directors) and their Relatives</u>		
- <u>Payables for Expenses</u>		
Sharad B. Shah	104.41	101.06
Ronak K. Shah	154.68	137.90
Khushboo R. Shah	44.67	39.17
Total	303.76	278.13
- <u>Unsecured Borrowings</u>		
Sharad B. Shah	173.64	949.71
Ronak K. Shah	56.77	354.84
Total	230.40	1,304.55

32. Financial instruments

(₹ '000)

Particulars	As at 31.03.2023		
	fair value through profit and loss	fair value through other comprehensive income	Amortised cost
	Rs.	Rs.	Rs.
Financial asset			
Trade receivables	-	-	20,676.45
Cash and cash equivalents	-	-	1,502.88
Total Financial asset	-	-	22,179.34
Financial liability			
Borrowings	-	-	12,741.47
Trade Payable	-	-	8,708.51
Total Financial liability	-	-	21,449.98



Sungrace Pharma Private Limited

Notes forming part of the financial statements (2022-23)

Particulars	As at 31.03.2022		
	fair value through profit and loss	fair value through other comprehensive income	Amortised cost
	Rs.	Rs.	Rs.
Financial asset			
Trade receivables	-	-	19,590.53
Cash and cash equivalents	-	-	1,407.21
Total Financial asset	-	-	20,997.74
Financial liability			
Borrowings	-	-	13,347.06
Trade Payable	-	-	10,855.71
Total Financial liability	-	-	24,202.77

33. Additional Regulatory Information

a. Ratios

-	Current ratio (in times)	Current year	Previous year	Variance(%)
	Numerator	1.50	1.35	11.06
	Current Assets			
	Denominator	0.94	1.27	-25.97
	Current Liabilities			
-	Debt-Equity ratio (in times)	Current year	Previous year	Variance(%)
	Numerator	0.94	1.27	-25.97
	Total Debt			
	Shareholder's Equity			

Decrease is mainly due to decrease in Unsecured loans from Directors as compared to previous year.

-	Debt service coverage ratio (in times)	Current year	Previous year	Variance(%)
	Numerator	4.55	3.69	23.43
	Earnings available for debt service (Net Profit before taxes + Non-cash operating expenses like depreciation and other amortizations + Interest + other adjustments like loss on sale of Fixed assets)			
	Denominator	4.55	3.69	23.43
	Debt Service (Interest & Lease Payments + Principal Repayments)			

-	Return on equity ratio (in %)	Current year	Previous year	Variance(%)
	Numerator	25.29	35.93	-29.61
	Net Profits after taxes - Preference Dividend (if any)			
	Denominator	25.29	35.93	-29.61
	Average Shareholder's Equity			

Decrease is mainly due to increase of Average Shareholder's equity as compared to prev. year



Sungrace Pharma Private Limited

Notes forming part of the financial statements (2022-23)

<i>Inventory Turnover Ratio (no. of times)</i>		Current year	Previous year	Variance(%)
Numerator	Denominator	3.82	5.14	-25.80
Revenue from Operations	Average Inventory (Opening + Closing balance / 2)			

Variance is primarily on account of decrease in Revenue along with decrease in average Inventories.

<i>Trade receivables turnover ratio (in times)</i>				Variance(%)
Numerator	Denominator	2.63	3.96	-33.45
Revenue from Operations	Average Accounts Receivable (Opening + Closing balance / 2)			

Variance is primarily on account of decrease in Revenue along with decrease in average trade receivables.

<i>Trade payables turnover ratio (in times)</i>		Current year	Previous year	Variance(%)
Numerator	Denominator	3.73	5.07	-26.44
Net Credit Purchases	Average Trade Payables (Opening + Closing balance / 2)			

There is decrease in Trade Payable Turnover Ratio on account of decrease in purchases in line with decrease in operations.

<i>Net capital turnover ratio (in times)</i>		Current year	Previous year	Variance(%)
Numerator	Denominator	4.57	8.83	-48.27
Revenue from Operations	Working Capital= Total Current Assets- Total Current Liabilities			

Variance is primarily on account of decrease in net sales along with increase in working capital.

<i>Net profit ratio (in %)</i>		Current year	Previous year	Variance(%)
Numerator	Denominator	5.76	3.73	54.44
Net Profit after tax	Revenue from Operations			

Variance is primarily on account of decrease in net profits along with decrease in revenue.

<i>Return on capital employed (in %)</i>		Current year	Previous year	Variance(%)
Numerator	Denominator	20.16	24.95	-19.21
Earning before interest and taxes	Capital Employed (Tangible Net Worth + Total Debt + Deferred Tax Liability)			

<i>Return on investment (in %)</i>		Current year	Previous year	Variance(%)
Numerator	Denominator	6.00	8.00	-25.00
Income generated from invested funds	Cost of Investment			

b. Loans or advances to specified persons

No loans or advances in the nature of loans are granted to promoters, directors, KMPS and the related parties (as defined under Companies Act, 2013,) either severally or jointly with any other person, that are repayable on demand or without specifying any terms or period of repayment.



Sungrace Pharma Private Limited

Notes forming part of the financial statements (2022-23)

c. Details of benami property held

No proceedings have been initiated on or are pending against the Company for holding benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made thereunder.

d. Borrowing secured against current assets

Name of the bank	Quarter	Nature of the Current Asset	As per Unaudited Books of Accounts	Amount as per Quarterly Return & Statements	Amount of Difference	Reason for Discrepancies
The Ahmedabad Mercantile Co Op bank Limited	March, 2023	Inventory- Stock in Trade	12,332.28	13,533.28	1,201.00	Reported Amount to bank is including promotional items and without adjustment of expired/ near expiry date stock.
	March, 2023	Trade Receivables	20,676.45	19,963.57	(712.88)	Entire Trade receivables reported net of advances received and without passing reconciliation entries to Bank

e. Wilful defaulter

The Company has not been declared wilful defaulter by any bank or financial institution or other lender.

f. Relationship with struck off companies

The Company has no transactions with the companies struck off under Section 248 of the Companies Act, 2013 or Section 560 of the Companies Act, 1956.

g. Registration of charges or satisfaction with Registrar of Companies (ROC)

There are no charges or satisfaction yet to be registered with Registrar of Companies (ROC) beyond the statutory period.

h. Compliance with approved scheme(s) of arrangements

The Company has not entered into any scheme of arrangement which has an accounting impact on current or previous financial year.

i. Utilisation of borrowed funds and share premium

No funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person or entity, including foreign entities ("Intermediaries") with the understanding, whether recorded in writing or otherwise, that the Intermediary shall lend or invest in party identified by or on behalf of the Company (Ultimate Beneficiaries). The Company has not received any fund from any party (Funding Party) with the understanding that the Company shall whether, directly or indirectly lend or invest in other persons or entities identified by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries



Sungrace Pharma Private Limited

Notes forming part of the financial statements (2022-23)

j. Undisclosed income

There is no income surrendered or disclosed as income during the current or previous year in the tax assessments under the Income Tax Act, 1961, that has not been recorded previously in the books of account.

k. Details of crypto currency or virtual currency


The Company has not traded or invested in crypto currency or virtual currency during the current or previous year.

l. Utilisation of borrowings availed from banks and financial institutions

The borrowings obtained by the company from banks and financial institutions have been applied for the purposes for which such loans were taken.

34. Previous year's figures have been regrouped / reclassified wherever necessary to correspond with the current year's classification / disclosure.

As per our report of even date
For, B H MANGAROLIA & CO.
Chartered Accountants
(FRN 105972W)



(P B MANGAROLIA)
Partner
M. No. 124424



UDIN:23124424BGXRCW5995
Place: Ahmedabad
Date: 29.05.2023

For and on behalf of the Board



(Sharad B. Shah)
Director
DIN:00747131

(Ronak K. Shah)
Director
DIN:03350856